New targeted drug trial aims to control advanced cancers with specific gene fault
NCT ID NCT05544552
Summary
This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tumors. It is for adults who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Cleveland Clinic - Main Campus
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute (DCI) - Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Gustave Roussy (Institut de Cancerologie Gustave-Roussy)
Villejuif, 94805, France
-
Institut Claudius Regaud, IUCT-Oncopole
Toulouse, 31059, France
-
Institut de Cancerologie de L'Ouest (ICO)
Saint-Herblain, 44805, France
-
Linear Clinical Research Limited
Nedlands, Washington, 6009, Australia
-
Macquarie University
Macquarie Park, New South Wales, 2109, Australia
-
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York, 10021, United States
-
NEXT Barcelona - Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Madrid, 28223, Spain
-
Peter MacCallum Cancer Research Unit
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Seattle Cancer Care Alliance (SCCA) - South Lake Union
Seattle, Washington, 98109, United States
-
Tasman Oncology
Southport, Queensland, 4215, Australia
-
UMass Memorial Medical Center
Worchester, Massachusetts, 01655, United States
-
Vall d'Hebron Institut d'Oncologia (VHIO)
Barcelona, 08035, Spain
-
Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.